Obstetrics & Gynecology Doctors in Hanford, CA Accepting Medicare

4 Obstetrics & Gynecology doctors found. Showing 1 - 4

Thomas Schram Enloe, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 1157 W Lacey Blvd, Hanford, CA 93230 Phone: 559-582-1041    Fax: 559-582-4829

Dr. David Francis Cryns, DO Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 329 W. 8th St., Suite 101, Hanford, CA 93230 Phone: 559-587-4532    Fax: 559-589-1867

Sayed Mohammed Basel, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 460 Greenfield Ave, Suite 1, Hanford, CA 93230 Phone: 559-584-0141    Fax: 559-584-5711

Minh Tien Tang, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 329 W 8th St, Suite 101, Hanford, CA 93230 Phone: 877-960-3426

News Archive

ACP signs on to Code for Interactions with Companies released by CMSS

The American College of Physicians (ACP), the largest medical specialty organization and the second-largest physician group in the United States, has signed on to the CMSS Code for Interactions with Companies, released today by the Council of Medical Specialty Societies (CMSS). The intent of the code is to guide medical societies developing policies and procedures that safeguard the independence and transparency of their programs, policies, and advocacy positions in relationships with industry.

Neptune, Acasti completes preclinical program comparing CaPre with Lovaza

Neptune Technologies & Bioressources Inc. subsidiary, Acasti Pharma Inc., reports the completion of its preclinical program designed to compare the lipid management effects of Acasti's drug candidate CaPre versus prescription drug Lovaza.

‘Missing' schizophrenia heritability found

Researchers have matched up single nucleotide polymorphism sets with clinical syndromes to show that previously identified genetic variants can account for nearly all cases of schizophrenia.

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

Read more Medical News

› Verified 5 days ago